Molecular Partners AG (MOLN) — Cash Flow Reinvestment Rate

Latest as of March 2022: 0.57x

Molecular Partners AG (MOLN) has a Cash Flow Reinvestment Rate of 0.57x as of March 2022, reinvesting CHF93.61 Million (capex CHF380.00K plus investments CHF-93.23 Million) from operating cash flow of CHF163.56 Million. Explore Molecular Partners AG capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.57x
(Capex + Investments) / Operating CF

Total Reinvested

CHF93.61 Million
Capex + Investments

Operating Cash Flow

CHF163.56 Million
CHF

Capital Expenditures

CHF380.00K
CHF

Molecular Partners AG Cash Flow Reinvestment Rate (2015–2022)

Historical reinvestment intensity for Molecular Partners AG across 2 annual periods. Also explore total assets of Molecular Partners AG for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Molecular Partners AG (2015–2022)

Year-by-year capital reinvestment analysis for Molecular Partners AG. For live market cap and broader valuation context, see Molecular Partners AG stock valuation.

Year Reinvestment Rate Total Reinvested (CHF) Operating CF Capex YoY Change
2022 0.86x CHF102.54 Million CHF118.57 Million CHF1.42 Million ▲ +7.0%
2015 0.81x CHF21.41 Million CHF26.50 Million CHF1.39 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow